Close this search box.

Dealmaker Sabry retiring from Roche after 14-year stint

ARTICLE | Management Tracks

Pharma has struck multiple 10-figure deals under Sabry’s watch, expands role for BD head Boris Zaitra

By Paul Bonanos, Director of Biopharma Intelligence

May 28, 2024 11:21 PM UTC

Prolific dealmaker James Sabry is stepping away from Roche (SIX:ROG: OTCQX:RHHBY) and its Genentech Inc. subsidiary after a 14-year run with the company, including the past six years as the pharma’s global head of partnering.

Roche described Sabry’s departure as his retirement from the company, although it’s not clear what next steps may lie ahead for the executive…